Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 58 Carcinoma, Non-Small-Cell Lung 36 Urinary Bladder Neoplasms 33 Neoplasm Metastasis 20 Lung Neoplasms 20 Ovarian Neoplasms 19 Lymphoma, Large B-Cell, Diffuse 18 Cholangiocarcinoma 15 Neoplasms 14 Nasopharyngeal Carcinoma 14 Biliary Tract Neoplasms 14 Triple Negative Breast Neoplasms 13 Colorectal Neoplasms 12 Breast Neoplasms 12 Carcinoma, Transitional Cell 11 Non-Muscle Invasive Bladder Neoplasms 10 Fallopian Tube Neoplasms 10 Recurrence 9 Gallbladder Neoplasms 8 Sarcoma 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Bile Duct Neoplasms 6 Uterine Cervical Neoplasms 5 Osteosarcoma 5 Lymphoma, Non-Hodgkin 5 Lymphoma 5 Hodgkin Disease 5 Endometrial Neoplasms 5 Melanoma 4 Gastrointestinal Neoplasms 4

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × Gemcitabine × 90 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡